Bayer is highlighting new and expanded patient throughput and workflow features in its artificial intelligence (AI) portfolio at the RSNA meeting in Chicago.
Bayer is showcasing its next-generation CT technology, MEDRAD Centargo CT Injection system, which is pending clearance by the U.S. Food and Drug Administration (FDA), the company said.
It is also highlighting details on its recently launched Calantic SPARK program, an accelerator program for medical imaging app developers that supports them to bring new products to market. The program will initially focus on North America and Europe.
In addition, Bayer announced collaboration agreements with app developers Quantib, ClariPi, and EXINI Diagnostics which it hopes will expand the capacity of its medical imaging platform Calantic Digital Solutions. The new collaboration agreements broaden options for thoracic and neurological diseases on the Calantic platform by including tools to aid in breast and prostate imaging.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
